StemCell Therapy

The healthcare sector has started to utilize the patient engagement technology so that they can offer them with better treatments.

FREMONT, CA:Technology is continuously changing the face of the healthcare industry at an extremely high rate. If the new technologies are utilized effectively, healthcare organizations will meet the increasing demand and efficiently offer better service to the patients. Here are some of the trends related to patient engagement technology that the healthcare sector can follow.

Utilization of artificial intelligence (AI) and machine learning

Presently, the healthcare sector has also started to utilize technologies like machine learning and AI. However, it is expected that the utilization of these technologies will increase rapidly in the coming years and offer various benefits. Moreover, if the sector enhances their research and clinical trials' efficiency by developing new tools, it will help them to fulfill the demands of the patients and even make the process cost-efficient.

The opinion about technologies like chatbots is also changing because the patients can directly book their appointments or solve their queries related to medications. Moreover, Conversational AI will also help the patients and the healthcare providers to converse among each other through written or spoken language.

Advancement of personalized treatment using predictive medicine

Presently various new applications are coming up that are prioritizing predictive healthcare so that the patients get introduced to more effective treatments. Wearables are a useful technology that can be used for capturing the data for treatment purposes. Therefore, the healthcare sector is applying wearable technologies to create opportunities for organizations to offer personalized treatment to the patients.

Furthermore, the data that has been collected from the smartwatches and trackers will allow the healthcare facilities to get a better idea and start treatment of the issues in advance before it starts showing symptoms in the patients. The doctors can also prescribe the medications accurately due to precision medicine as it is data driven.

The continuous growth of digital platforms

As the consumers want a better and sophisticated service so that they can manage their necessities, the popularity of the all-in-one platform is increasing. In the healthcare sector, the consumers are also expecting a user-friendly and customer-first digital experience, and this all-in-one platform can offer them with it.

However, in the healthcare sector, it is necessary to apply the new technologies in their present business model and IT infrastructure to offer better treatment to their patients.

See also:Top Machine Learning Companies

See original here:
How Patient Engagement Technology is Transforming the Healthcare... - Healthcare Tech Outlook

Genomics Market report highlights CAGR value fluctuations during the forecast period of 2020-2025 for the market. The report presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. A market research analysis and estimations carried out in this Genomics report aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Furthermore, market research report also provides a watchful investigation of the current state of the market which covers several market dynamics.

Businesses can accomplish unparalleled and comprehensive insights along with the best acquaintance of the emerging market opportunities with this Genomics market research report. This report is structured with the meticulous efforts of innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry experts, and forecasters. By understanding clients requirements precisely, this report brings together business and product information for the sustainable growth in the market. Two of the major tools of market analysis employed are SWOT analysis and Porters Five Forces Analysis. The Genomics report is generated with a nice combination of advanced industry insights, practical solutions, talent solutions and the use of latest technology which gives an excellent user experience.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPTE100000730/

MARKET INTRODUCTION

The global genomics market is expected to reach US$ 32,995.3 Mn in 2025 from US$ 14,728.6 in 2017. The market is estimated to grow with a CAGR of 10.8% from 2018-2025.

Genomics market is segmented by technology, product & services, application and end user. Global genomics market, based on technology was segmented into sequencing, microarray, PCR, nucleic acid extraction and purification, and others. Global genomics market, based on the product & services was segmented into instruments/systems, consumables, and services. The genomics market, based on application was segmented into diagnostics, drug discovery & development, precision/personalized medicine, agriculture & animal research and others. The genomics market is bifurcated on basis of end user such research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users.

Key Competitors In Market are

The top 10 industry players operating in the market of genomics across the globe includes Thermo Fisher Scientific Inc., Illumina Inc., and Eurofins, Qiagen, Agilent Technologies, BGI, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Danaher, and GE Healthcare. For instance, in October 2017, MGI Tech, a subsidiary corporation of BGI, launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200 in Shenzhen, China. MGI also launched a modular NGS workstation, MGIFLP along with other products. And the launch expanded the business of the company in global genomics market.

TOC of Market Report Contains:

MARKET SCOPE

The objective of the study is to describe, define, and forecast the genomics market by technology, product & services, application, end user and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall market.

Market segmentation:

Genomics Market to 2025 Global Analysis and Forecasts by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, and Others), Product & Service (Instruments/Systems, Consumables, and Services), Application (Diagnostics, Drug Discovery and Development, Precision/Personalized Medicine, Agriculture & Animal Research, and Others) End User (Research Centers, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Click to buy full report with all description:https://www.theinsightpartners.com/buy/TIPTE100000730/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read more:
Genomics Market 2020 Insight On The Analysis By Essential Factors And Trends In Industry By 2025 - 3rd Watch News

Post by Lisa Carroll, Canadian Public Sector Lead, Microsoft Canada

As the COVID-19 pandemic unfolded earlier this year, healthcareprovidersacross the country found themselves like so many other organizations having to urgently reinvent ways to operate, provide patient care, manage supply chains and deploy resources, with many of the usual ways of doing things suddenly off the table.With every second counting,the industryquicklyrealizedthat the immediate implementation andredeploymentof valuable resources wasanimperative.

It hasnt been easy, butamidst the crisisand uncertainty, we have continued to persevere.I amtrulyamazed at the incredibletransformationour healthcaresystemhasimplemented in such a short period of time.Healthcare providersquickly pivoted to newways of operating, while also coming together as a community todevelopnew solutionsforsafe and securetesting toprotect the health and wellbeing of our Citizens andsupporting the initiation ofthereopening our economy.

Microsoft has been working closely withpartnersand customersthroughout the pandemicto solve these big challenges by connecting health data and systems in the cloud, making health work better for patients and providers, and advancing precision medicine.Akey priority for us is providingthese organizationswith the peaceof mind to remainconfidentthattheir data is beingprocessed bytrustedMicrosoft platformsthat aresecure and compliant by designmeetingmore than70industry-widecertifications.Recognizing that thehealthcare sector is particularly vulnerable tocyber-attacksduring times of crisis, Microsofthas also recentlyimplementedanintensified monitoring and takedown ofpotentialthreatswith anemphasis on protecting critical services,such ashospitals.

I wanted to take a moment to pause and recognize the resilience and ingenuity of a smallsamplingof the many organizations who areresponding and protectingour communities across Canada:

POWERING THE HEART OF VIRTUAL CARE

POWERING INSIGHTS FOR BETTER PATIENT OUTCOMES

ACCELERATING HEALTHCARE DELIVERY

There is something to be said about hownecessityand emergencyoften drive innovation, andwe are especially proud to becollaboratingwith Citizen Care Pod Corporation,WZMH Architects, PCL Construction and Insight Enterpriseson a new initiative todeveloped with the intent torevolutionizetheaccessibilityand safety of COVID-19 testing.The Citizen Care Pod is a customizable unit outfitted with the capabilities to enable turnkey mobile COVID-19 testing in high-traffic business environments and communities with the goal to expedite testing, screening, and eventually vaccination on mass scale.

Utilizing modular construction methods, PCL Construction is manufacturing and assembling the pods by retrofitting shipping containers with customizable options to support rapid delivery and installation toany site, including high-traffic or remote locations.Eachpodis equipped with a suite of intelligent, customizable technologies powered by Microsofts trusted Azure and AI platform,which support a safe and secure testing environment for patients and front-linehealthcareworkers.

CANADIANS ARESTRONGER TOGETHER

Each passing day of this pandemic bringsnew challenges,butitsbeenincredible to see howgovernments and healthcare organizations across the countryarequickly reinventingways to operateasmany of the changes put in place today will help medical professionals deliver personalized care to Canadians in new, innovative ways in the post-COVID world.

We are proud to be part of new solutionsand new partnerships as we join together in our common cause.As the saying goes, it takes a village and at Microsoft we are committed to being there for all of our customers and partners to weather this storm together.

To learn more about Microsoft solutions that can help in the fight against COVID-19, visitaka.ms/healthcareincanada

More here:
Supporting Canada's Healthcare Industry with Trusted Technology in Response to COVID-19 - Microsoft

Ripple Science Logo

ANN ARBOR, Mich. (PRWEB) July 09, 2020

Ripple Science today announced their partnership with Lakeside Life Science, a diagnostic research organization that is performing a clinical study to determine antibodies using Medsentials COVID-19 IgG/IGM Rapid Test Cassette. With 11.6 Million cases and over 500,000 deaths worldwide, the public health crisis that is COVID-19 has accelerated organizations to adopt technology like Ripple, which shorten time-to-market for biopharma solutions.

Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts, leading to valuable time and cost savings. Medsentials test is already available for high-complexity CLIA certified labs. Lakesides study will be validating the test in a clinical setting. Paul Allard, COO of Lakeside Life Science, explained how Ripple helps with a very short timeline: Ripple is streamlining the whole clinical study process for us. Our timeline for this study is incredibly short. Normally we need four to six months for study start up and 18 months to enroll patients. Our goal is to complete this entire study under a month and a half.

Allard anticipates a follow-on study to determine how long a person has the antibodies. Lakeside, an expert in testing validation, has confirmed that Medsentials IgM/IgG antibody test outperform antibody tests from well-known industry healthcare providers. Allard said, In moving to a long-term study, we want high confidence in our antibody testing solution and are delighted at Medsentials results and how easy the tests are to use.

Lakeside is using Ripple to quickly recruit and track patients from small, underserved community centers that dont have access to standard testing or the tools to manage clinical studies. Patients from these small centers can benefit from access to testing and are more representative of the general population.

Clinical studies are known for their complex nature beginning with recruiting patients to continual patient engagement, especially for follow-up months after the study commences. Chiao-ih Hui, COO for Medsential, is pleased that many of the study complexities are being removed. I love that Ripple is making this highly involved and complex clinical process easier and streamlined. This will accelerate and provide a model for getting our solution to point-of-care settings and to vulnerable populations who have the most need for these solutions.

President and CEO of Ripple Science, Peter Falzon commented, With COVID-19, the way we conduct clinical trials has changed and there is a heightened sense of urgency. The team at Ripple Science is dedicated to enabling clinical research teams to work remotely and adopt virtual research methods, while boosting recruitment and retention.

About Lakeside Life Science:Lakeside Life Science was founded in January of 2015, by W. Jeffrey and Paul Allard to bring patients and communities together to advance personalized medicine through the research and development of novel diagnostic tests. Lakeside provides the resources for their clients to bring their assays from invention to FDA clearance/approval, while putting patient needs first.

About Medsential: Medsential LLC is a US FDA registered company that develops, manufactures, and distributes a broad range of medical products to customers. Established in 2005, Medsential is an ISO certified medical device company with the capabilities to manufacture and assemble a broad range of products. Medsential has an extensive distribution channel, salesforce, engineering platform, and production team to bring quality products to global markets.

About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up. Ripple Sciences flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.

To learn more, please visit: https://www.ripplescience.com

Share article on social media or email:

Read more:
Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential's Point-of-Care COVID-19 Antibody Test...

Dublin, July 03, 2020 (GLOBE NEWSWIRE) -- The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.

The global digital genome market was valued at US$ 11,065.31 million in 2019 and is projected to reach US$ 20,812.81 million by 2027; it is expected to grow at a CAGR of 8.4% during 2020-2027.

The growth of the digital genome market is mainly attributed to factors such as the increasing prevalence of chronic diseases and growing funding for genomics. However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the world's largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently.

Moreover, in August 2018, Boston, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the company's mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death.

Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end-user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

Key Topics Covered

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 Global Digital Genome Market - By Product1.3.2 Global Digital Genome Market - By Application1.3.3 Global Digital Genome Market - By End-user1.3.4 Global Digital Genome Market - By Geography

2. Digital Genome Market - Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. Global Digital Genome Market - Market Landscape4.1 PEST Analysis4.1.1 North America - PEST Analysis4.1.2 Europe - PEST Analysis4.1.3 Asia-Pacific - PEST Analysis4.1.4 Middle East and Africa - PEST Analysis4.1.5 South and Central America - PEST Analysis4.2 Expert Opinion

5. Digital Genome Market - Key Market Dynamics5.1 Market Drivers5.1.1 Growing Funding for Genomics5.1.2 Increasing Prevalence of Chronic Diseases5.2 Market Restraints5.2.1 Dearth of Skilled Professionals5.3 Market Opportunities5.3.1 Increasing Technological Advancement in Digital Genome Field5.4 Future Trends5.4.1 Increasing Demand for Personalized Medicines5.5 Impact analysis

6. Digital Genome Market - Global Analysis6.1 Global Digital Genome Market Revenue Forecast and Analysis6.2 Global Digital Genome Market, By Geography - Forecast and Analysis6.3 Market Positioning of Key Players

7. Digital Genome Market Analysis - By Product7.1 Overview7.2 Digital Genome Market Revenue Share, by Product (2019 and 2027)7.3 DNA/RNA Analysis7.4 Sequencing and Analyzer Instruments7.5 Sequencing and Analysis Software7.6 Sequencing Chips7.7 Sample Prep Instruments

8. Digital Genome Market - By Application8.1 Overview8.2 Digital Genome Market, by Application, 2019 and 2027 (%)8.3 Diagnostics8.4 Drug Discovery8.5 Academic Research8.6 Personalized Medicine8.7 Agricultural8.8 Others

9. Digital Genome Market - By End-user9.1 Overview9.2 Digital Genome Market, by End-user, 2019 and 2027 (%)9.3 Diagnostics & Forensic Labs9.5 Academic Research Institutes9.6 Hospitals9.7 Other End-users

10. Digital Genome Market - Geographic Analysis10.1 North America: Digital Genome Market10.2 Europe: Digital Genome Market10.3 Asia-Pacific: Digital Genome Market10.4 Middle East & Africa: Digital Genome Market10.5 South and Central America: Digital Genome Market

11. Impact of COVID-19 Pandemic on Global Digital Genome Market11.1 North America: Impact Assessment of COVID-19 Pandemic11.2 Europe: Impact Assessment of COVID-19 Pandemic11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Digital Genome Market - Industry Landscape12.1 Overview12.2 Growth Strategies Done by the Companies in the Market, (%)12.3 Organic Developments12.4 Inorganic Developments

13. Company Profiles13.1 Thermo Fisher Scientific Inc.13.2 F. Hoffmann-La Roche Ltd.13.3 Illumina, Inc.13.4 QIAGEN13.5 GenomeMe13.6 NanoString Technologies, Inc.13.7 BD13.8 bioMerieux SA13.9 GenMark Diagnostics, Inc.13.10 Perkin Elmer, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/bi9red

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post:
Global Digital Genome Market and COVID-19 Impact Assessment 2019-2027 - A $20+ Billion Industry Opportunity with Lucrative Growth Projected for...

The global market for companion diagnostics reached nearly $4.4 billion in 2016. This market is expected to grow from nearly $5.5 billion in 2017 to $25.1 billion in 2022 at a compound annual growth rate (CAGR) of 35.5% for forecasted period 2017 to 2022.

Report Scope:

The scope of the report encompasses the major types of diagnostics technologies that have been used, the various industry structures such as the lab developed tests (LDTs) sector, and the major applications being commercialized and developed by a wide range of company types. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11778

Report Includes:

An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments. Analyses of market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry. Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments. Profiles of major players as well as a list of current companies that have new companion diagnostics products in development.

REASONS FOR DOING THE STUDY

Companion diagnostics represent part of the personalized medicine sector. The companion diagnostics segment has expanded significantly over the past decade from5% to 15% of the overall personalized medicine sector, and is expected to reach close to 25% in the next five years.

CDx are being used both to predict outcome (efficacy and safety) and to monitor the response. The predictive or selective characteristics of CDxs have demonstrated clearvalue to the pharmaceutical industry. For example, CDx assays are being used to select patients for clinical trials, resulting in a smaller number of subjects needed togenerate positive data, which has a clear positive impact on the resources spent in clinical development.

Cancer is increasingly recognized as a heterogenous disease that requires tailored treatment. Patients are being selected for specific chemotherapies and newer targetedtherapeutics with greater confidence that their specific cancers will respond.

SCOPE OF REPORT

The scope of the report encompasses the major types of diagnostics technologies that have been used, the various industry structures such as the lab developed tests (LDTs) sector, and the major applications being commercialized and developed by a wide range of company types. It analyzes current market status, examines future marketdrivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed.

More Info of Impact [emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11778

See the rest here:
Companion Diagnostics Market Applications, Types and Growing Trends in Industry, Gross Margin and Forecast size COVID-19 2022 - 3rd Watch News

Technavio has been monitoring the tumor (cancer) profiling market and it is poised to grow by USD 4.85 billion during 2020-2024, progressing at a CAGR of 10% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005559/en/

Technavio has announced its latest market research report titled Global Tumor (Cancer) Profiling Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Co., bioMrieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Increasing cancer research and funding has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Tumor (Cancer) Profiling Market 2020-2024: Segmentation

Tumor (Cancer) Profiling Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40128

Tumor (Cancer) Profiling Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The tumor (cancer) profiling market report covers the following areas:

This study identifies the increasing adoption of personalized medicine as one of the prime reasons driving the tumor (cancer) profiling market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Story continues

Technavio's SUBSCRIPTION platform

Tumor (Cancer) Profiling Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY TECHNOLOGY

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005559/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Read more:
Analysis of COVID-19 Impact: Tumor (Cancer) Profiling Market 2020-2024 | Increasing Cancer Research and Funding to Augment Growth | Technavio - Yahoo...

A special thank you to Kathleen Dickson and Dr. John Bergeron for pointing out that yes, indeed, there are also many women who have made and continue to make significant contributions to health. We have added their additions below, but this list is by no means complete.

From open heart surgery to child-resistant containers, prestigious awards and bombs (not that kind), Canada has a long history of Canadians whose ideas and inventions have played huge roles in defining this nations healthcare.

DNA and cancer

Nada Jabado at McGill affiliated Childrens Hospital is a pioneer in pediatric cancer and her discovery of the role of what is known as the epigenome that marks the DNA in our genes in cancer. She is a leader in innovation in Health research and recognized for her leadership in the application of discoveries to address brain tumours in children.

Insulin

Perhaps the most famous health innovation to come out of Canada, if such a thing can be measured. The arrival of insulin has saved countless lives since its creation in 1922 when Frederick Banting and Charles Best isolated and extracted insulin from the pancreas of dogs. Their Nobel Prize arrived swiftly thereafter in 1923.

Read the original post:
28 cool health things that started with a Canadian - Regina Leader-Post

Personalized medicine is tailoring of a treatment to a specific patient i.e. designing medicine treatment on the basis of diagnosis, disease condition, patient history, body physics, and other factors related to patients and diseases. Personalized medicine is also known as precision medicine, stratified medicine, or P4 medicine.

Read Report Overview https://www.transparencymarketresearch.com/personalized-medicines-market.html

In personalized medicine, diagnostic analysis is often conducted for selecting suitable and best treatments based on the patients genetic content or other molecular or cellular analysis. Personalized medicine has best response and highest safety margin to ensure enhanced patient care by allowing every patient to attain earlier diagnosis, risk assessment, and best treatment. Additionally, personalized medicine offers opportunities to improve health care by lowering overall treatment costs.

Rise in the prevalence of various types of cancer, affordability of personalized medicine therapy in cancer drugs and various other disease indications, less side-effects of personalized medicine therapy, high adoption in developed markets, and development of innovative drugs are factors driving the global personalized medicine market. However, high competition among existing market players, stringent government regulations regarding product approval, and lack of awareness among the rural population in developing economies are likely to hamper the market in the next few years.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=394

The global personalized medicine market is can be segmented based on product, application, distribution channel, and region. In terms of product, the market has been categorized into personalized medicine therapeutics, personalized medicine diagnostics, personalized nutrition & wellness, and personalized medical care. The personalized medicine therapeutics segment has been sub-categorized into pharmaceuticals, genomic medicine, and medical devices. The personalized medicine therapeutics segment is anticipated to hold the largest share of the global personalized medicine market during the forecast period, owing to rise in the prevalence of various types of cancer and chronic diseases.

Based on application, the global personalized medicine market has been divided into cancer management, infectious diseases, central nervous system (CNS) disorders, blood transfusion safety, coagulation therapy, diabetes, autoimmune diseases, cardiovascular diseases, neurology, and psychiatry. The cancer management segment is likely to hold the major share of the global market during the forecast period. Based on distribution channel, the market can be categorized into hospitals pharmacies, retail pharmacies, dietary care centers, and others. Rising prevalence of chronic diseases is likely to boost the market in the near future.

Request for Analysis of COVID19 Impact on Personalized Medicine Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=394

Geographically, the global personalized medicine market can be segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America dominates the personalized medicine market, followed by Europe. The market in Asia Pacific and Latin America is developing. This trend is expected to continue during the forecast period as well.

Availability of large patient pool, expansion of the health care industry, and rise in government investments in improvement of health care are anticipated to propel the market in these regions. The personalized medicine market in countries such as Brazil, China, and India is projected to expand at a substantial growth rate during the forecast period, due to rise in awareness among people about usage of the personalized medicine therapy to treat various types of cancer and rapid innovations in personalized medicine for various other disorders.

Pre Book Personalized Medicine Market https://www.transparencymarketresearch.com/checkout.php?rep_id=394&ltype=S

Major players operating in the global personalized medicine market are Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline plc., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V., Eli Lilly and Company, Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Biogen, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, and Sanofi Genzyme.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Follow this link:
Personalized Medicine Market: Rise in the Prevalence of Various Types of Cancer to Drive the Global Market - Science Examiner

DUBLIN--(BUSINESS WIRE)--Jun 29, 2020--

The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.

The global digital genome market was valued at US$ 11,065.31 million in 2019 and is projected to reach US$ 20,812.81 million by 2027; it is expected to grow at a CAGR of 8.4% during 2020-2027.

The growth of the digital genome market is mainly attributed to factors such as the increasing prevalence of chronic diseases and growing funding for genomics. However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the world's largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently.

Moreover in August 2018, Nebula Genomics, a Massachusetts-based company announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the company's mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death.

Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

Key Topics Covered

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

1.3.1 Global Digital Genome Market - By Product

1.3.2 Global Digital Genome Market - By Application

1.3.3 Global Digital Genome Market - By End-user

1.3.4 Global Digital Genome Market - By Geography

2. Digital Genome Market - Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Digital Genome Market - Market Landscape

4.1 PEST Analysis

4.1.1 North America - PEST Analysis

4.1.2 Europe - PEST Analysis

4.1.3 Asia-Pacific - PEST Analysis

4.1.4 Middle East and Africa - PEST Analysis

4.1.5 South and Central America - PEST Analysis

4.2 Expert Opinion

5. Digital Genome Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Funding for Genomics

5.1.2 Increasing Prevalence of Chronic Diseases

5.2 Market Restraints

5.2.1 Dearth of Skilled Professionals

5.3 Market Opportunities

5.3.1 Increasing Technological Advancement in Digital Genome Field

5.4 Future Trends

5.4.1 Increasing Demand for Personalized Medicines

5.5 Impact analysis

6. Digital Genome Market - Global Analysis

6.1 Global Digital Genome Market Revenue Forecast and Analysis

6.2 Global Digital Genome Market, By Geography - Forecast and Analysis

6.3 Market Positioning of Key Players

7. Digital Genome Market Analysis - By Product

7.1 Overview

7.2 Digital Genome Market Revenue Share, by Product (2019 and 2027)

7.3 DNA/RNA Analysis

7.4 Sequencing and Analyzer Instruments

7.5 Sequencing and Analysis Software

7.6 Sequencing Chips

7.7 Sample Prep Instruments

8. Digital Genome Market - By Application

8.1 Overview

8.2 Digital Genome Market, by Application, 2019 and 2027 (%)

8.3 Diagnostics

8.4 Drug Discovery

8.5 Academic Research

8.6 Personalized Medicine

8.7 Agricultural

8.8 Others

9. Digital Genome Market - By End-user

9.1 Overview

9.2 Digital Genome Market, by End-user, 2019 and 2027 (%)

9.3 Diagnostics & Forensic Labs

9.5 Academic Research Institutes

9.6 Hospitals

9.7 Other End-users

10. Digital Genome Market - Geographic Analysis

10.1 North America: Digital Genome Market

10.2 Europe: Digital Genome Market

10.3 Asia-Pacific: Digital Genome Market

10.4 Middle East & Africa: Digital Genome Market

10.5 South and Central America: Digital Genome Market

11. Impact of COVID-19 Pandemic on Global Digital Genome Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Digital Genome Market - Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.4 Inorganic Developments

13. Company Profiles

13.1 Thermo Fisher Scientific Inc.

13.2 F. Hoffmann-La Roche Ltd.

13.3 Illumina, Inc.

13.4 QIAGEN

13.5 GenomeMe

13.6 NanoString Technologies, Inc.

13.7 BD

13.8 bioMerieux SA

13.9 GenMark Diagnostics, Inc.

13.10 Perkin Elmer, Inc.

See the article here:
Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company -...

UTRECHT, Netherlands, June 29, 2020 /PRNewswire/ -- Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, today announced the appointment of Joris Schuurmans as CEO and Dirk Pollet and Maja Sanders as Supervisory Board members. Novalis Biotech Incubation will invest in Cergentis' growth potential.

Incoming CEO Joris Schuurmans has extensive experience in the molecular diagnostics and biopharmaceutical industry. He held senior executive positions at Biocartis and MyCartis, and recently lead Skyline Dx' melanoma program prior to transitioning to his role at Cergentis.

Joris Schuurmans commented: "I am very excited by the opportunity to join Cergentis at this pivotal stage. Cergentis has developed an impressive array of products and services in the field of genetic engineering, and is extremely well-positioned to enter the molecular diagnostics field with products that elucidate DNA variants in tumors that cannot be well-analyzed with current technologies. We are all excited to embark on our mission to improve diagnosis and treatment of cancer patients."

Dr. Jan Groen, Chairman of the Board: "A heartfelt gratitude to outgoing CEO Jan Dekker, who laid the foundation for Cergentis to take the next step to accelerate the development and commercialization of its unique TLA technology for cancer diagnostics. We are pleased to welcome Joris as new CEO. Joris has an excellent international track record in the biotech industry. We are also very pleased with the appointment of our new Board members Maja and Dirk."

Dr. Dirk Pollet, industry veteran, heralded the acquisition of Multiplicom by Agilent as CEO of Multiplicom, is currently CEO of Enzyre. Maja Sanders currently holds supervisory roles at various (non-)profit organizations and has built up extensive managerial experience in the private equity industry.

Novalis Biotech Incubation, a venture capital investment fund, is investing in Cergentis.

Wim Van Criekinge, Co-founder of Novalis: "We are pleased to invest in Cergentis. Their technology is unique and allows the most advanced genome characterization to date."

About Cergentis

Cergentis is a genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans)genes and gene editing events. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. TLA is a well-established technology thatprovides unique and critical advantages in the implementation of personalized medicine. For more information: cergentis.com.

SOURCE Cergentis

https://www.cergentis.com

Originally posted here:
Cergentis Appoints New CEO and Board Members - PRNewswire

Biopreservationis the process of improving safety of food products and extending their shelf life through utilization of their controlled or natural microflora. Biopreservation process makes the use of lactic acid bacteria (LAB) as the main tool and they are mainly considered as generally recognized as safe (GRAS) products. The global biopreservation market is estimated to witness substantial growth over the tenure of assessment owing to the high prevalence of various chronic diseases. Lactic acid bacteria can restrict the growth of the various microorganisms, which comprises fungi, yeasts, and bacteria.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1340

Increased prevalence of various chronic diseases such as obesity, diabetes, renal diseases, and cardiac illnesses is likely to work in favor of the global biopreservation market in the years to come. According to the National Diabetes Statistics Report 2020, around 34.2 million people in the US, which is just over 1 in 10 and 10.5 % of the US population, suffer from diabetes. In addition, dearth of organ donors for the purpose of transplantation is likely to augment the demand for regenerative medicines. This factor is likely to boost the global biopreservation market over the tenure of assessment.

Growing investment in research and development in drug discovery is likely to impact the growth of the global biopreservation market in the near future. Rise in the number of bio-banks for storing various biological products utilized in medical research is likely to augur well for the rapid expansion of the market. Furthermore, as coronavirus spreads across the globe killing thousands, the demand for medical research to find a solution to contain the disease is on the rise. As such, the demand for biopreservation is expected to swell riding on the back of spread of coronavirus across the globe.

Increased Spending on Research and Development Activities to Bolster Demand

In the global biopreservation market, biobanking is estimated to experience considerable growth over the timeframe of analysis. Biobanks refer to the biorepositories that preserve and store various biological samples utilized in medical research. Rising demand for biospecimens for supporting contemporary researches in genomics and personalized medicine is likely to escalate the adoption of biobanking. With the rise in biobanking, the demand for biopreservation is predicted to rise in the near future.

Regenerative medicines in the global biopreservation market are likely witness lucrative growth over the analysis timeframe. Rising adoption of regenerative medicines for treating severe to life-threatening conditions is likely to foster growth of the regenerative medicines. Increased prevalence of chronic diseases has often led to various organ deformities, which has generated demand for organ transplantation. Regenerative medicines comprise regeneration or engineering of human tissues, organs or cells to establish or restore normal functioning of organs. Dearth of organ donors is also expected to drive the demand for regenerative medicines in the years to come.

On the other hand, stringent regulations pertaining to the production of biopreservation items is likely to hamper the growth of the global biopreservation market. Furthermore, emergence of storage techniques that could store such products at room temperature is further likely to limit growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1340

Driven by Rising Incidences of Lifestyle Diseases, US to Lead the Market

U.S. biopreservation market is predicted to account for a sizeable chunk of the market and is expected to experience substantial growth over the period of assessment. Rising prevalence of various lifestyle diseases such as renal diseases, obesity, and diabetes often leads to organ damages, which is likely to offer lucrative growth opportunities for the biopreservation market in the US.

The UK is another promising region for the global biopreservation market and the region is estimated to continue with the similar trend over the years of assessment. Such growth of the country is ascribed to the augmented support from the government for smooth functioning of the biobanks. The government also assists in the networking of biobanks such as UK biobank and international collaborations for the expansion of the scope of biobanking. This factor is likely to bolster the growth of the biopreservation market in the region.

Presence of Several Market Players to Bolster Demand in the Market

Some of the prominent industry players found in the global biopreservation market compriseBioLife Solutions, Inc., Thermo Fisher Scientific Inc., Atlanta Biologicals Inc., Custom Biogenic Systems, Panasonic Biomedical, and Taylor-Wharton International LLC.The global biopreservation market is regarded as a fragmented one owing to the presence of several market players. Furthermore, the market is likely to be characterized by acquisitions, mergers, and product launches.

Avail the Discount on this Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1340

Original post:
Biopreservation Market Latest Trends and Analysis Future Growth Study by 2025 - Cole of Duty

GE Healthcare Enterprise Tech Ecosystem Series

Summary

GE Healthcare is tapping the power of 3D printing, genomics, mobile health, artificial intelligence, cloud, big data, remote patient monitoring, IoT, and precision & personalized medicine to offer connected care and improve workflow.

The company provides mentorship and investment support to startups through its in-house accelerator programs, such as Five.eight and Edision[X], and cco-develop solutions through own and partner innovation centers.

Grab a Free sample copy of the report from here:https://www.researchmoz.us/enquiry.php?type=S&repid=2706993

GE Healthcare acquired tech companies, namely, Monica Healthcare and Zenith Technologies.

The companys venture investment arm is called GE Ventures (GEV), which invest in both healthcare and non-healthcare sectors. The investments are made in Nuvolo Technologies, Vineti, and Genome Medical to name a few.

The report provides information and insights into GE Healthcares tech activities, including Insights of its digital transformation strategies, innovation centers, and accelerator programs Overview of technology initiatives covering partnerships and innovative product and solution launch Insights on each technology initiative including technology theme, objective, and benefits Details of estimated ICT budgets and major ICT contracts

Scope

GE Healthcare created a remotely managed private cloud-as-a-service dubbed GE Infrastructure Xchange (GEIX) powered by OpenStack and run through Rackspace for hosting all its applications. The company focuses on developing software-based digital solutions that use technologies like predictive, preventive, and perspective analytics to provide caregivers with increased access to data, analytics, connectivity, and insights on operational processes and workflows. In 2019, GE Healthcare partnered with NASSCOM CoE-IoT, an innovation hub based in India. In 2019, the company launched its first start-up collaboration program known as Edison[X].

Browse complete report description And Full TOC @https://www.researchmoz.us/enquiry.php?type=E&repid=2706993

Reasons to Buy

Gain insights into GE Healthcares tech operations. Gain insights into its tech strategies, innovation centers, and accelerator initiatives. Gain insights into its technology themes under focus. Gain insights into various technology introduction, adoption, and partnership strategies of GE Healthcare.

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Media Release @https://www.researchmoz.us/pressreleaseFollow me on Blogger:https://trendingrelease.blogspot.com/

Link:
Addressing the potential impact of coronavirus disease (COVID-19) on GE Healthcare-Enterprise Tech Ecosystem Series Market: Quantitative Analysis from...

Lab-on-chipsis an integrated miniaturized device used in the laboratory operations on a single micro-process chip in small scale. Lab-on-chip is also called as micro-total analytical system. Complex tests can be performed on a single chip by combining microfluidics and microelectronics using Lab-on-chips. Lab-on-chip has its main application in biotechnological and medical applications such as medical diagnostics, chemical synthesis and the study of complex cellular process, thus providing quick diagnosis.

Lab Chip devices are influencing the Laboratory Testing market where trace samples are to be analysed in the field if medical examination. Being handy, portable, and easy to use these devices are extensively used in hospitals and various surgical centres as well, thus promising the growth of global Lab Chip Devices Market in the near future.

Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/3299

Diagnostics will hold the largest segment globally, because of the growing demand for diagnostics with high speed, efficiency, and sensitivity of results with accuracy. Diagnostics segment is expected to expand at the highest CAGR of 11.3% over the period from 2018 to 2026. Day by day increasing global population is continuously increasing the number of patients with diseases and thus the demand for microfluidic systems for diagnosis, treatment, and monitoring of these diseases. The Lab on chips contributes to the rise in personalized medicine, drug discovery and life science research, and growing need for high speed diagnostics. These factors will lead the diagnostics segment across different regions of the world.

North America has the highest revenue share in 2017 due to more demand for microfluidic products in the pharma, diagnostic, and clinical sectors for its cost-effectiveness and multi functionality. In North America, market players are developing advanced microfluidic products continuously. The U.K. holds highest share in Europe market with a significant growth. Whereas in APAC, the demand is mainly concentrated in China and India, due to the increasing population and popularity of conventional biological laboratories.

Some of the key players in the global lab-on-chips application market are EMD Millipore, Life Technologies Corporation, Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Bio-Rad Laboratories.

Based on application:

Clinical Diagnostics

Genomics

In vitro Diagnostics

Point of Care Diagnostics

Proteomics

Drug Discovery

Others (Biodefense, Food Pathogen Identification, and Environmental Contamination)

Based on the end user type:

Biotechnology and Pharmaceutical Companies

Hospitals

Forensic Laboratories

Diagnostics Centers

Academic & Research Institutes

Go here to read the rest:
Lab-On-Chips Market: Opportunities and Forecast Assessment, 2018 to 2025 - Cole of Duty

Proteomics refers to the field of study of the expression of genetic information at the protein level (proteome). Mass spectrometry (MS) is one of the high-growth areas in automation in proteomics. Automation feature includes temperature control, reagent handling and integrated robotics and a bar code reader to handle many samples at a point of time. Automation is a leading feature in this market as profits are based on the number of samples hence high throughput is very important and this can be easily achieved through automation.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10064997

Market DynamicsThe rapidly growing demand for personalized medicine, R&D expenditure, technological advancements, and increased funding for proteomics projects are prime drivers for automation in the proteomics market. Moreover, need for consistency in quality and a high cost of error also act as growth drivers.Lack of planning for technology development, low priority for lab automation among small and medium-sized laboratories and high initial setup cost put constraints on the market.

Market SegmentationThe globallab automation marketis segmented by equipment and software (automated liquid handling, microplate readers, standalone robots, software and informatics, ASRS), by applications (clinical diagnostics, drug discovery, genomics solutions, proteomics solutions), by type of automation (modular automation and total lab automation), by end users (biotech and pharma, hospitals and private labs, academics and research institutes).

Geographic AnalysisNorth America and Europe lead the global lab automation in proteomics market along with Canada and Japan. Asia Pacific and Latin American countries represent emerging markets.

Request For Full Report:https://www.kennethresearch.com/sample-request-10064997

Key PlayersSome of the major players in the market includeGilent Technologies Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, GE Healthcare, Luminex Corporation, Merck, PerkinElmer Inc., Thermo Fisher Scientific, Inc. and Waters Corporation.

About UsKenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation.

Contact UsKenneth ResearchEmail:[emailprotected]Phone:+1 313 462 0609

Read more:
Lab Automation in Proteomics Market By Brand and major players 2020-2022 - 3rd Watch News

The market research report published by QYResearch is a brilliant, in-depth, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Nucleic Acid Amplification Testing market. It informs readers about key trends and opportunities in the global Nucleic Acid Amplification Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include , F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories Nucleic Acid Amplification Testing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528651/global-nucleic-acid-amplification-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Nucleic Acid Amplification Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Nucleic Acid Amplification Testing Market Segment By Type:

, Target Amplification Systems, Probe Amplification Systems, Signal Amplification Nucleic Acid Amplification Testing

Global Nucleic Acid Amplification Testing Market Segment By Application:

, Infectious Diseases, Cancer, Personalized Medicine, Genetic and Mitochondrial Disorders

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include , F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories Nucleic Acid Amplification Testing

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1528651/global-nucleic-acid-amplification-testing-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Nucleic Acid Amplification Testing Revenue1.4 Market Analysis by Type1.4.1 Global Nucleic Acid Amplification Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 Target Amplification Systems1.4.3 Probe Amplification Systems1.4.4 Signal Amplification1.5 Market by Application1.5.1 Global Nucleic Acid Amplification Testing Market Share by Application: 2020 VS 20261.5.2 Infectious Diseases1.5.3 Cancer1.5.4 Personalized Medicine1.5.5 Genetic and Mitochondrial Disorders1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends by Regions2.1 Nucleic Acid Amplification Testing Market Perspective (2015-2026)2.2 Nucleic Acid Amplification Testing Growth Trends by Regions2.2.1 Nucleic Acid Amplification Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Nucleic Acid Amplification Testing Historic Market Share by Regions (2015-2020)2.2.3 Nucleic Acid Amplification Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Nucleic Acid Amplification Testing Market Growth Strategy2.3.6 Primary Interviews with Key Nucleic Acid Amplification Testing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Nucleic Acid Amplification Testing Players by Market Size3.1.1 Global Top Nucleic Acid Amplification Testing Players by Revenue (2015-2020)3.1.2 Global Nucleic Acid Amplification Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Nucleic Acid Amplification Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Nucleic Acid Amplification Testing Market Concentration Ratio3.2.1 Global Nucleic Acid Amplification Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Nucleic Acid Amplification Testing Revenue in 20193.3 Nucleic Acid Amplification Testing Key Players Head office and Area Served3.4 Key Players Nucleic Acid Amplification Testing Product Solution and Service3.5 Date of Enter into Nucleic Acid Amplification Testing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Nucleic Acid Amplification Testing Historic Market Size by Type (2015-2020)4.2 Global Nucleic Acid Amplification Testing Forecasted Market Size by Type (2021-2026) 5 Nucleic Acid Amplification Testing Breakdown Data by Application (2015-2026)5.1 Global Nucleic Acid Amplification Testing Market Size by Application (2015-2020)5.2 Global Nucleic Acid Amplification Testing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Nucleic Acid Amplification Testing Market Size (2015-2020)6.2 Nucleic Acid Amplification Testing Key Players in North America (2019-2020)6.3 North America Nucleic Acid Amplification Testing Market Size by Type (2015-2020)6.4 North America Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 7 Europe7.1 Europe Nucleic Acid Amplification Testing Market Size (2015-2020)7.2 Nucleic Acid Amplification Testing Key Players in Europe (2019-2020)7.3 Europe Nucleic Acid Amplification Testing Market Size by Type (2015-2020)7.4 Europe Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 8 China8.1 China Nucleic Acid Amplification Testing Market Size (2015-2020)8.2 Nucleic Acid Amplification Testing Key Players in China (2019-2020)8.3 China Nucleic Acid Amplification Testing Market Size by Type (2015-2020)8.4 China Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 9 Japan9.1 Japan Nucleic Acid Amplification Testing Market Size (2015-2020)9.2 Nucleic Acid Amplification Testing Key Players in Japan (2019-2020)9.3 Japan Nucleic Acid Amplification Testing Market Size by Type (2015-2020)9.4 Japan Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Nucleic Acid Amplification Testing Market Size (2015-2020)10.2 Nucleic Acid Amplification Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Nucleic Acid Amplification Testing Market Size by Type (2015-2020)10.4 Southeast Asia Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 11 India11.1 India Nucleic Acid Amplification Testing Market Size (2015-2020)11.2 Nucleic Acid Amplification Testing Key Players in India (2019-2020)11.3 India Nucleic Acid Amplification Testing Market Size by Type (2015-2020)11.4 India Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Nucleic Acid Amplification Testing Market Size (2015-2020)12.2 Nucleic Acid Amplification Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Nucleic Acid Amplification Testing Market Size by Type (2015-2020)12.4 Central & South America Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 F. Hoffmann-La Roche13.1.1 F. Hoffmann-La Roche Company Details13.1.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue13.1.3 F. Hoffmann-La Roche Nucleic Acid Amplification Testing Introduction13.1.4 F. Hoffmann-La Roche Revenue in Nucleic Acid Amplification Testing Business (2015-2020))13.1.5 F. Hoffmann-La Roche Recent Development13.2 Becton13.2.1 Becton Company Details13.2.2 Becton Business Overview and Its Total Revenue13.2.3 Becton Nucleic Acid Amplification Testing Introduction13.2.4 Becton Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.2.5 Becton Recent Development13.3 Dickinson and Company13.3.1 Dickinson and Company Company Details13.3.2 Dickinson and Company Business Overview and Its Total Revenue13.3.3 Dickinson and Company Nucleic Acid Amplification Testing Introduction13.3.4 Dickinson and Company Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.3.5 Dickinson and Company Recent Development13.4 Beckman Coulter13.4.1 Beckman Coulter Company Details13.4.2 Beckman Coulter Business Overview and Its Total Revenue13.4.3 Beckman Coulter Nucleic Acid Amplification Testing Introduction13.4.4 Beckman Coulter Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.4.5 Beckman Coulter Recent Development13.5 Abbott Laboratories13.5.1 Abbott Laboratories Company Details13.5.2 Abbott Laboratories Business Overview and Its Total Revenue13.5.3 Abbott Laboratories Nucleic Acid Amplification Testing Introduction13.5.4 Abbott Laboratories Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.5.5 Abbott Laboratories Recent Development13.6 Illumina13.6.1 Illumina Company Details13.6.2 Illumina Business Overview and Its Total Revenue13.6.3 Illumina Nucleic Acid Amplification Testing Introduction13.6.4 Illumina Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.6.5 Illumina Recent Development13.7 Siemens Healthineers13.7.1 Siemens Healthineers Company Details13.7.2 Siemens Healthineers Business Overview and Its Total Revenue13.7.3 Siemens Healthineers Nucleic Acid Amplification Testing Introduction13.7.4 Siemens Healthineers Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.7.5 Siemens Healthineers Recent Development13.8 bioMerieux13.8.1 bioMerieux Company Details13.8.2 bioMerieux Business Overview and Its Total Revenue13.8.3 bioMerieux Nucleic Acid Amplification Testing Introduction13.8.4 bioMerieux Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.8.5 bioMerieux Recent Development13.9 Novartis13.9.1 Novartis Company Details13.9.2 Novartis Business Overview and Its Total Revenue13.9.3 Novartis Nucleic Acid Amplification Testing Introduction13.9.4 Novartis Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.9.5 Novartis Recent Development13.10 Bio-Rad Laboratories13.10.1 Bio-Rad Laboratories Company Details13.10.2 Bio-Rad Laboratories Business Overview and Its Total Revenue13.10.3 Bio-Rad Laboratories Nucleic Acid Amplification Testing Introduction13.10.4 Bio-Rad Laboratories Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.10.5 Bio-Rad Laboratories Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:
Nucleic Acid Amplification Testing Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026| F....

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Artificial Intelligence in Healthcare market.

Trusted Business Insights presents an updated and Latest Study on Artificial Intelligence in Healthcare Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Artificial Intelligence in Healthcare market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Artificial Intelligence in Healthcare Market, Market Research and Industry Forecast Report, 2019-2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Artificial Intelligence in Healthcare Market

The global artificial intelligence in healthcare market size was valued at USD 2.5 billion in 2018 and is anticipated to grow at a CAGR of 41.5% over the forecast period. The growing need for lowering healthcare costs, growing importance of big data in healthcare, rising adoption of precision medicine, and declining hardware costs are some factors driving growth. In addition, increasing applicability of AI-based tools in medical care and rise in venture capital investments can be attributed to the surge in demand for this technology. For instance, CarePredict, Inc. uses AI technology to monitor changes in behavior patterns and activity for early detection of health issues.Increasing number of cross-industry partnerships is expected to boost adoption of AI in the healthcare sector, which is further responsible for its lucrative growth rate. In September 2018, GNS Healthcare entered into a cross-industry partnership with Alliance and Amgen for clinical trials in oncology. The collaboration was aimed at applying data from clinical trials and Artificial Intelligence (AI) to identify factors that expedite treatment responses in metastatic Colorectal Cancer (CRC) patients. Likewise, Microsoft announced partnership with Apollo Hospitals, one of the prominent healthcare systems in India, in March 2018. The partnership is focused on developing and deploying new machine learning models for predicting the risk of developing cardiac diseases and aid doctors in treatment planning.

Number of artificial intelligence start-ups in healthcare sector has significantly grown in past few years, and the trend is expected to be the same in the coming years, which will in turn, will positively impact the market. Rise in venture capital funding in this domain is a key factor accountable for increase in the number of these start-ups. For instance, in July 2018, Kleiner Perkins and GV invested USD 21 million in Viz.ai-an AI in healthcare start-up. Similarly, HealthPlix Technologies Pvt. Ltd. raised USD 3 million in a Series A funding round led by Kalaari capital and IDG Ventures India in July 2018. Some of the prominent venture capitalist firms operating in this sector are ACCEL PARTNERS, Data Collective, General Catalyst Partners, Khosla Ventures, and others.Adoption of AI in healthcare is growing, with rise in focus on improving quality of patient care by utilizing artificial intelligence in various aspects of healthcare services, such as virtual assistants & surgeries. The AI-based tools, such as clinical decision support systems & voice recognition software, aid in streamlining workflow processes in hospitals and improving medical care, thereby enhancing patient experience.Moreover, shortage of physicians in some countries is anticipated to increase the demand for AI technology. Few companies are engaged in developing such virtual assistants. For instance, in September 2017, Nuance Communications unveiled an AI-based virtual assistance designed specifically for healthcare providers and patients. The incorporation of AI in healthcare has various benefits for both patients as well as healthcare providers. For instance, AI enables personalized care, based on health condition and past medical history. Moreover, AI-based apps can be used for continuous monitoring of health, which would in turn ensure timely care & treatment and can eventually reduce hospital stay.

Component Insights of Artificial Intelligence in Healthcare Market

Software solutions segment held the largest share in the artificial intelligence in healthcare market in 2018. The development of AI-based software solutions for healthcare is one of the key factors boosting segment growth. For instance, Nuance Communications develops a software named Dragon Medical One. According to Nuance Communications, this software can help healthcare companies as well as providers transcribe a physicians speech into an Electronic Health Record (EHR) via natural language processing. Companies such as Google, IBM, and Microsoft are develop and offer machine learning framework.Hardware segment is expected to grow with a CAGR 40.0% over the forecast period. The growing need for hardware platforms with high computing power to operate several AI-based software is one of the major factors contributing to segment growth. Processers such as ASICs, MPUs, GPUs, and FPGAs are used in AI-based platforms designed for use in healthcare.The growth of services segment can majorly be attributed to the rising need for integration and deployment of AI solutions. Moreover, the rise in adoption of AI platforms in the healthcare sector has increased the need for maintenance and support services, which are imperative to keep the devices functional.

Application Insights of Artificial Intelligence in Healthcare Market

Clinical trials emerged as the largest segment in terms of application and was valued at USD 620.5 million in 2018. Unsuccessful clinical trials generally lead to delay/failure of launch of drug candidates in the market. In order to automate clinical trial processes, pharmaceutical companies are focusing on integrating them with artificial intelligence. According to an analysis published by Accenture, the annual value for clinical trial participant identifier is estimated to reach USD 13 billion by 2026 on using this technology.

The adoption of artificial intelligence in robotic-assisted surgery platforms is anticipated to grow at significant pace and the segment is expected to show a lucrative CAGR over the forecast period. Such robots can integrate information from actual surgical experiences to form new improved insights. Such improvement is expected to enhance overall surgical outcome, thereby, enhancing consumer trust on AI integration across surgery centers. Virtual assistant is another lucrative healthcare application of AI technology. AI-enabled virtual assistant can lower the number of physician visits required by a patient, as it can assist by remotely monitoring a patients symptoms and delivering alerts to the respective healthcare professional. In addition, these virtual assistants can save about 20% of the time a nurse by omitting unnecessary visits.Regional InsightIn 2018, North America dominated the global market. Rising adoption of healthcare IT solutions, well-established healthcare sector, and availability of funding for developing AI capabilities are some of the factors contributing to the growth of the market in the region. The U.S. held the largest revenue share in North America, and is anticipated to maintain its position over the forecast period. Advancements in technology and several government initiatives are aiding adoption of digital platforms in life sciences, which can also be attributed to this share.Asia Pacific is expected to emerge as the fastest growing region. Improving infrastructure for healthcare IT, rising number of AI start-ups, and gradually increasing adoption of advanced technologies are some of the factors contributing to market growth. Rise in number of government initiatives for AI technology in this region is also expected to support growth. For instance, in March 2019, in South Korea, the Ministry of Science and ICT announced that it would initiate a trial service of an AI-based precision medicine service named Dr. Answer, in December 2019.

Market Share Insights of Artificial Intelligence in Healthcare Market

IBM Corporation; NVIDIA Corporation; Nuance Communications, Inc.; Microsoft; Intel Corporation; and DeepMind Technologies Limited are among the major players. Investments in R&D, collaborations with other industry participants, and service differentiation are among the key strategies adopted by these players for gaining a competitive edge. For instance, in February 2019, IBM Corporation announced a 10-year partnerships, including an investment of USD 50 million in AI research, with Vanderbilt University Medical Center and Brigham and Womens Hospital.

p2 Segments covered in the reportThis report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented global artificial intelligence in healthcare market report on the basis of component, application, and region:

Component Outlook (Revenue, USD Million, 2019 2030)

Software Solutions

Hardware

Services

Application Outlook (Revenue, USD Million, 2019 2030)

Robot-assisted Surgery

Virtual Assistants

Administrative Workflow Assistants

Connected Machines

Diagnosis

Clinical Trials

Fraud Detection

Cybersecurity

Dosage Error Reduction

Quick Read Table of Contents of this Report @ Artificial Intelligence in Healthcare Market, Market Research and Industry Forecast Report, 2019-2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
Artificial Intelligence in Healthcare MARKET REPORT 2020 TO 2028 MARKET ANALYSIS, SIZE, SHARE, TRENDS, KEY PLAYERS, DRIVERS AND FORECAST - Cole of...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Clinical Oncology Next Generation Sequencing market.

Trusted Business Insights presents an updated and Latest Study on Clinical Oncology Next Generation Sequencing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Clinical Oncology Next Generation Sequencing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Clinical Oncology Next Generation Sequencing Market

The global clinical oncology next generation sequencing market size was estimated at USD 627.2 million in 2018. Significant increase in the adoption of genome-focused pharmacology for cancer treatment is expected to provide growth avenues for the market. NGS serves as one of the highly advanced genomic techniques for the analysis of mutations that lead to cancer progression.The growth of the market is supplemented by decrease in the cost of genetic sequencing, advancements in the field of personalized medicine and oncology, rise in prevalence of cancer, globally, and increase in adoption of this technique over single-gene testing. Since this technique is more reliable than Sanger sequencing for diagnosis, the market is expected to witness substantial growth over the forecast period.

Breakthrough advancements in the development of genetic-based tests for oncology and other disorders during the past few years have significantly propelled market growth. Next generation sequencing technology offers a better understanding of tumor mechanism, thus enabling rational drug design. As a result, more products are expected to get commercialized in the near future.A rise in oncology-related spending is further expected to fuel market growth in the coming years. Government organizations are focused on encouraging patients to regularly undergo diagnostic examinations to reduce oncology-related healthcare expenditures. As per data estimates, healthcare expenditure is anticipated to rise significantly, thereby influencing the adoption of NGS diagnostics platforms.The biotechnology industry is marked by high competition and so is the NGS market for clinical as well as research applications. Prominent participants are actively involved in R&D to develop novel rapid, small, and less expensive platforms. Service providers are embracing the trend of increasing the amount of constructed sequence reads for each cycle run.Commercially available sequencing platforms analyze both DNA and RNA samples. Key players aim to increase the utility of high throughput technologies for clinical applications. The acquisition of smaller entities operating in the market is also one of the strategic initiatives adopted by players to maintain a competitive position. For instance, in May 2018, Illumina acquired Edico Genome to accelerate data analysis for its next generation sequencing platforms.

Technology Insights of Clinical Oncology Next Generation Sequencing Market

Targeted sequencing in clinical oncology accounted for the largest revenue share in 2018 and is expected to maintain its share over the forecast period. Targeted sequencing and resequencing encompasses shortest read lengths and is one of the conventional forms of commercially available sequencing technology. Moreover, focused panels for targeted cancer sequencing aid in the reduction of cost burdens owing to reduction in the amount of data to be analyzed. As targeted cancer sequencing evaluates a limited gene-set, it can be used to analyze variations in rare tumor sub-clones with greater sensitivity and deep coverage.The whole-genome sequencing segment is expected to grow at the fastest rate through 2025. Application of whole genome sequencing technology for comparisons between tumor tissue and normal tissue in clinical oncology is attributive to segment growth. Developed rapid, large-capacity sequencers such as HiSeq and MiSeq series find application in largescale whole genome sequencing.Workflow InsightsNGS workflow includes library preparation, sample enrichment, sample quality assurance, DNA tagging, sequencing, DNA quantification, genetic data assemble, data storage and analysis, and interpretation. Sequencing accounted for the largest share in the clinical oncology NGS market as it is the most important and crucial step in the entire process and involves the usage of sophisticated platforms. Continuous R&D has led to the introduction of novel, benchtop, or portable NGS sequencing platforms, thereby complimenting market growth. Moreover, NGS platforms are expected to witness lucrative growth throughout the forecast period owing to the expected increase in adoption and usage rates of whole-genome sequencing.

Application Insights of Clinical Oncology Next Generation Sequencing Market

Next generation sequencing finds application in the field of clinical oncology for screening, companion diagnostics, and others. The adoption of NGS-based molecular diagnosis for oncology has increased as this technology allows concurrent sequencing of several target genes and provides rich diagnostic markers for the development of molecular diagnostic assays.Application of NGS technology in the field of oncology ensures early diagnosis so that treatment measures can be taken in time. Therefore, the arrival of NGS for cancer diagnosis has opened many new frontiers in the field. For instance, large-scale projects such as International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) have issued data from thousands of tumors across major cancer types. This data can be used to have a comprehensive overview of cancerous cells and help enhance prognostic and therapeutic applications.The market for companion diagnostics is expected to grow significantly in the coming years owing to numerous benefits offered by the technique in the field of oncology. Currently, available companion diagnostic products are applicable for non-small cell lung cancer, melanoma, colorectal, ovarian, and breast cancers.End-use InsightsBy way of end use, the clinical oncology next generation sequencingmarket has been segmented into hospitals, clinics, and laboratories. Laboratories held a prominent share in the market for clinical oncology NGS and this trend is likely to continue over the forecast period. The hospitals segment is expected to register a significant CAGR through 2025. Rise in adoption of NGS services in hospitals to determine the rate of disease progression and scale-up the appropriate treatment regimen for cancer is anticipated to influence growth in this segment.

Provision of clinical services by leading players in the market such as Illumina, which includes CLIA certified tests for predisposition screening, is anticipated to boost revenue in the coming years. Clinics utilize NGS technology to identify novel cancer mutations, for genetic testing for hereditary cancer syndrome, for personalized oncology treatment, and for detection of circulating DNA for cancer.

Regional Insights of Clinical Oncology Next Generation Sequencing Market

North America occupied the largest share in the global market in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure. Moreover, high prevalence of cancer, growing demand for personalized medicine, well-developed healthcare facilities, and availability of novel diagnostics techniques, especially in the field of oncology, can be attributed to the estimated market share of the region. Additionally, growing morbidity and mortality due to cancer has increased the need for development of novel therapies, thereby driving this regional market.Asia Pacific is expected to be the fastest-growing region throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Other factors contributing to this growth are untapped markets in emerging economies. The market is continuously driven by rise in cancer incidence across Asia Pacific. China dominates the cancer burden in the region, followed by India, Japan, Indonesia, and the Republic of Korea. The top three types of cancer with his incidences in the region are breast, lung, and prostate cancer.

Market Share Insights of Clinical Oncology Next Generation Sequencing Market

The global market is marked by the presence of high competition among market players. Illumina and Roche account for a substantial share owing to wide product offerings in the field of next-generation sequencing for cancer. Other prominent players operating in this market space include Agilent; Thermo Fisher Scientific; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer, Inc.; Qiagen NV; Partek, Inc.; Pacific Bioscience, Inc.; Foundation Medicine; Oxford Nanopore Technologies Ltd.; Paradigm Diagnostics, Inc.; Caris Life Sciences; and Eurofins Scientific.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Clinical Oncology Next Generation Sequencing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented the globalclinical oncology next generation sequencing market report on the basis of technology, workflow, application, end use, and region:

Technology Outlook (Revenue, USD Million, 2019 2030)

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing

Workflow Outlook (Revenue, USD Million, 2019 2030)

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

Application Outlook (Revenue, USD Million, 2019 2030)

Screening

Sporadic Cancer

Inherited Cancer

Companion Diagnostics

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Hospitals

Clinics

Laboratories

Quick Read Table of Contents of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
How COVID-19 Pandemic Will Impact Clinical Oncology Next Generation Sequencing Market Business Opportunity, And Growth 2020-2026 - Cole of Duty

A research team led by Francesca Luca, Ph.D., associate professor of Wayne State Universitys Center for Molecular Medicine and Genetics, has published a study that annotated environmental components that can increase or decrease disease risk through changes in gene expression in 43 genes that could exacerbate or buffer the genetic risk for cardiovascular disease. Their results highlight the importance of evaluating genetic risk in the context of gene-environment interactions to improve precision medicine.

Interpreting Coronary Artery Disease Risk Through GeneEnvironment Interactions in Gene Regulation was published in Genetics, the journal of the Genetics Society of America.

The study, said Dr. Luca, also of the WSU Department of Obstetrics and Gynecology, illustrates that combining genome-wide molecular data with large-scale population-based studies is a powerful approach to investigate how genes and the environment interact to influence risk of cardiovascular disease.

By identifying regions of DNA important for endothelial cell response to different common environmental exposures, the researchers discovered that caffeine can influence the risk of cardiovascular disease. The study demonstrates the potentially beneficial and/or detrimental effects of certain environmental exposures on the cardiovascular disease risk differ depending on individual DNA sequence.

The study focused on cardiovascular disease, Dr. Luca said, because it is the leading cause of death, both in the United States and worldwide. Also, the disease is highly multifactorial, with large contributions from both environmental and genetic risk factors. By treating endothelial cells under a controlled environment, we can discover how these genetic and environmental risk factors influence each other at the molecular level, she said. Our lab has developed expertise in cardiovascular research, with additional projects using endothelial cells to develop new assays to test the regulatory activity of genetic variants. The approach outlined in this paper can be applied to many different diseases; for example, our lab has also focused on how bacteria in the human gut affect gene expression in the colon, and also on the effect of psychosocial stress on asthma.

While the work identified regions of the genome important for how endothelial cells respond to the environment and can influence the risk of cardiovascular disease, the researchers do not yet know exactly which genetic variants are directly responsible. A former graduate student, Cynthia Kalita, developed an assay to test thousands of genetic variants for gene regulatory activity. The researchers can test the variants discovered in their study using that assay to validate and explore the mechanisms by which they exert their effects, Dr. Luca said. They also are developing computational/statistical methods that can yield better personalized risk scores.

We have extended our approach to study cardiomyocytes, which are the muscle cells of the heart. Healthy heart tissue is difficult to obtain, so we have collaborated with researchers at the University of Chicago to derive cardiomyocytes from stem cells, Dr. Luca said. This will allow us to shift our focus from the vasculature to the heart itself, where we can study diseases like cardiomyopathies and arrhythmias.

As the cost of DNA sequencing continues to decrease, Dr. Luca expects that genetic testing will play a greater role in preventive health care. To fully realize the potential of precision medicine, we need to consider both genetic and environmental risk factors of disease, and how they interact. While there are already direct-to-consumer tests that prescribe an individualized diet based on DNA, these products currently offer no demonstrated clinical value. However, with very large numbers of individuals for whom we have both DNA sequencing and information on diet and lifestyle, we may one day be able to offer better recommendations.

Others involved in the study included Anthony Findley, an M.D./Ph.D. student; Allison Richards, Ph.D., a research scientist; Cristiano Petrini, of the Center for Molecular Medicine and Genetics; Adnan Alazizi, lab manager; Elizabeth Doman, of the Center for Molecular Medicine and Genetics; Alexander Shanku, Ph.D., research scientist; Gordon Davis, of the Center for Molecular Medicine and Genetics; Nancy Hauff, Department of Obstetrics and Gynecology; Yoram Sorokin, M.D., professor of Obstetrics and Gynecology; Xiaoquan Wen, of the Department of Biostatistics at the University of Michigan; and Roger Pique-Regi, Ph.D., associate professor of the Center for Molecular Medicine and Genetics, and of the Department of Obstetrics and Gynecology.

Link:
Researchers identify environmental components that affect gene expression in cardiovascular disease - The South End

REDMOND, Wash. June 18, 2020 On Thursday, Microsoft Corp. and Johns Hopkins Medicine (JHM) announced a five-year relationship centered on Microsofts Azure and analytical tools that will support new discoveries as part of JHMs inHealth precision medicine initiative. The work will bring together JHMs leading global research expertise with the power of Microsoft Azure, and its AI capabilities, to help advance JHMs discoveries that will benefit personalized health care. JHM will maintain total control over its data.

inHealth embodies Johns Hopkins commitment to precision medicine, using new tools to understand and manage patients health, informed by their broader health history and environment. This program integrates JHMs longstanding leadership in health care research and delivery with the expertise of the Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Whiting School of Engineering and Johns Hopkins University Applied Physics Lab.

In support of inHealth, JHM has established 16 Precision Medicine Centers of Excellence, where researchers are pursuing breakthroughs in numerous disease settings, such as prostate cancer and multiple sclerosis. JHM aims to have 50 centers in the next five years.

Ad StatisticsTimes Displayed: 1049244Times Visited: 9191

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Ethical use of patient data is a cornerstone of all of JHMs partnerships with patients, including this important work with Microsoft in precision medicine. All projects are compliant with all appropriate privacy regulations, and JHM maintains strict control over all data, including through the use of its Institutional Review Board and its internal Data Trust Council that reviews data use across JHM.

It is a distinct privilege to partner with many of the worlds leading physicians, scientists and engineers at JHM as they use Microsoft Azure and its AI and machine learning capabilities to support some of the most advanced research and breakthroughs in precision medicine, said Gregory Moore, M.D., Ph.D., corporate vice president of Microsoft Health. Im inspired by the collaboration and its bold goals to improve health for all by bringing together some of the worlds best minds in medicine and technology to deliver the future of medical science innovation.

JHM has previously used Microsoft services as JHM developed its pioneering Precision Medicine Analytics Platform (PMAP), a highly innovative data platform that allows collection and analysis information from a broad array of sources in a secure environment. This new agreement will enable inHealth to expand use of other Microsoft resources, such as advanced services, AI, machine learning and analytics.

More information about Johns Hopkins Medicine precision medicine work and inHealth can be found here.

Microsoft (Nasdaq MSFT @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

More here:
Microsoft Azure will become the preferred cloud platform for Johns Hopkins in Health precision medicine initiative - DOTmed HealthCare Business News